Immune cells trained to hunt MUC1 protein show promise in hard-to-treat myeloma
NCT ID NCT05411497
First seen Nov 04, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This early-phase trial tests a personalized therapy where a patient's own T-cells are trained to recognize and attack the MUC1 protein on myeloma cells. The study enrolls 5 adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goal is to check safety and find the best dose, while also watching for any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
Conditions
Explore the condition pages connected to this study.